glp-1-agonists

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

1. 45/100

   Unveiling Tirzepatide's Therapeutic Spectrum: A Dual GIP/GLP-1 Agonist Targeting Metabolic, Neurological, and Cardiovascular Health

   ✓ Peer-reviewed alzhub usefulness score 45 out of 100. International journal of endocrinology · 2025-10-01 · Drug development

   Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a groundbreaking treatment for Type 2 diabetes mellitus (T2DM) and obesity.

   • Treatments
   • Risk Factors
2. 45/100

   GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies

   ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of clinical medicine · 2025-09-24 · Drug development

   Glucagon-like peptide-1 (GLP-1) receptor agonists now serve as therapeutic agents for cardiovascular diseases (CVDs) beyond their original use for treating type 2 diabetes mellitus (T2DM).

   • Treatments
   • Risk Factors
3. 41/100

   The GLP-1 agonist semaglutide ameliorates cognitive regression in P301S tauopathy mice model via autophagy/ACE2/SIRT1/FOXO1-Mediated Microglia Polarization

   ✓ Peer-reviewed alzhub usefulness score 41 out of 100. European journal of pharmacology · 2025-01-26 · Drug development

   Tau hyper-phosphorylation has been recognized as an essential contributor to neurodegeneration in Alzheimer's disease (AD) and related tauopathies.

   • Brain Biology
   • Treatments
4. 76/100

   Exploring the neuroprotective role of GLP-1 agonists against Alzheimer's disease: Real-world evidence from a propensity-matched cohort

   ✓ Peer-reviewed alzhub usefulness score 76 out of 100. Journal of Alzheimer's disease reports · 2025-01-01 · Drug development

   GLP-1RA use was associated with a 70% reduced dementia risk, warranting further clinical evaluation.

   • Treatments
   • Risk Factors
5. 45/100

   Recent Advances and Therapeutic Benefits of Glucagon-Like Peptide-1 (GLP-1) Agonists in the Management of Type 2 Diabetes and Associated Metabolic Disorders

   ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Cureus · 2024-10-21 · Drug development

   Glucagon-like peptide-1 (GLP-1) agonists have emerged as a groundbreaking class of medications for managing type 2 diabetes and associated metabolic disorders.

   • Treatments
   • Risk Factors
6. 64/100

   All GLP-1 Agonists Should, Theoretically, Cure Alzheimer's Dementia but Dulaglutide Might Be More Effective Than the Others

   ✓ Peer-reviewed alzhub usefulness score 64 out of 100. Journal of clinical medicine · 2024-06-26 · Drug development

   Addressing the dysfunctions of all brain cell types in Alzheimer's disease (AD) should cure the dementia, an objective that might be achieved by GLP-1 agonist drugs, because receptors for GLP-1 are present in all of the main brain cell types, i.e., neurons, oligodendroglia, astroglia, microglia, endothelial cells and pericytes.

   • Treatments
   • Clinical Trials
   • Brain Biology

All topic tags with their study counts